Trending News

OCC Issues Bulletins on Customer Financial Record Protections and Politicized Debanking

Homebuyers Privacy Protection Act Signed Into Law, Restricting Trigger Leads

E-Verify Update: New Guidance for Employers on EAD Revocations

Responses to DOD Survey on Alternatives to TSCA High Priority Chemicals Due September 26, 2025

State Department Issues New, Immediate Requirement for Nonimmigrant Visa Applicants

Adjudicating Nonimmigrant Visa Applicants in Their Country of Residence — Implications for Employers and Employees

District Court Rejects First Amendment Challenge to California Climate Disclosure Requirements

This Week in 340B: August 5 – 11, 2025

DOL Resurrects PAID Program to Supervise Employers’ Self-Audits and Settlements of Potential FLSA and FMLA Violations

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Posted On Saturday, June 21, 2025
Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association
Posted On Saturday, June 21, 2025
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
Posted On Friday, June 20, 2025
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
Posted On Friday, June 20, 2025
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
Posted On Friday, June 20, 2025
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
Posted On Friday, June 20, 2025
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Posted On Friday, June 20, 2025
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
Posted On Friday, June 20, 2025
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Posted On Friday, June 20, 2025
PharmAla Files Preliminary Base Shelf Prospectus
Posted On Friday, June 20, 2025
Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
Posted On Friday, June 20, 2025
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
Posted On Friday, June 20, 2025
Rakovina Therapeutics Announces Share Consolidation Effective Date
Posted On Friday, June 20, 2025
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Posted On Friday, June 20, 2025
Moleculin Announces $5.9 Million Public Offering
Posted On Friday, June 20, 2025
INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time
Posted On Friday, June 20, 2025
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Posted On Friday, June 20, 2025
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Posted On Friday, June 20, 2025
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Posted On Friday, June 20, 2025
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Posted On Friday, June 20, 2025
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
Posted On Friday, June 20, 2025
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
Posted On Friday, June 20, 2025
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Posted On Friday, June 20, 2025
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
Posted On Friday, June 20, 2025
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
Posted On Friday, June 20, 2025

Print